Thinking about giving your cat CBD Oil? So am I. CBD for Pets?
It does seem to be a subject that requires thought because although we might jump right in
experimenting with our own health, we want to be careful with our pets.
We are their caretakers and do not want to make a mistake in caring for
them. I have noticed many holistic veterinarians see CBD oil as
beneficial to cats. All mammals have an endocannabinoid system and cats
are mammals. It stands to reason that the benefits humans reap from CBD
will also be the same for animals, but introducing something to your cat
may not be all that easy. Aside from that, will it do anything for your
cat? That depends on the problem. If you are hoping to restore a sense
of systemic balance to a nervous cat or help a cranky cat relax a
little, you are probably heading in the right direction. If you’re
looking to get your cat to clean its’ own litter box, that’s just not
going to happen. You have to have realistic expectations, and understand
it could take time to see a difference. That being said, you can
probably expect the same kind of results that you would see in a human.
Some relief from anxiety, improved ability to deal with stress, help
with inflammation, maybe even relief from some types of pain. I like to
think that CBD’s ability to drastically improve some types of seizures
in people would also apply to animal seizures. I have not seen any
information on studies with CBD for animal seizures, but I intend to
look for them. Is CBD oil safe for cats? You probably have heard that
cannabis is not safe for cats. You have heard correctly. For one thing,
cannabis contains THC, a big no no for animals, for another, cats have
trouble ridding their body of cannabis. But Some CBD comes from Hemp,
not cannabis. Specail CBD oil formulated for pets has only CBD in it,
the trace amounts of THC and other cannabinoids are filtered out to make
it safe for pets. And clever manufacturers of CBD for animals also add a
flavor that pets will like. Let’s go back to the first two problems I
mentioned. Animals suffer from anxiety and stress the same as humans do.
Sometimes an anxious pet can be annoying, but sometimes it is downright
heartbreaking to see an animal so nervous that it cowers even from the
person who loves it most. Sometimes a cat is o.k. with people, but
freaks around other cats. Or a cat can be ultra territorial and get
upset out of all proportion when another cat tries to play with it’s
favorite toy or enter an area the cat deems personal property. Can CBD
oil help with these things in cats? Make a cranky cat more sociable, a
scaredy cat less nervous, or a bully not so bullyish? Since I happen to
have cats with exactly these behavioral problems, I intend to find out.
I am going to experiment on my cats and tell you all about it. Hopefuly
this will help you decide to start or continue your cat on CBD oil.
First of all, I am not just doing this on a whim. My cats have real
problems that I think CBD can fix. Judging from what it has done for me,
I am willing to bet I get some positive results. As a matter of fact,
today I did kind of pre-experiment, experiment. I wanted to see if one
of my cats who has never turned her nose up at anything ever! would lick
the CBD oil off a paper plate without my having disguised it in any way.
I used the Nutra Life CBD oil for cats that has catnip oil in it. I
brought it to her and just put the plate down in front of her to see
what she would do. Of course I was hoping she would smell the catnip and
feast on the oil. She sniffed it a couple times and just when I was sure
she was going to lick it all up, she rubbed her face in it! So much for
that. I’m not sure whether that was successful or not. Moving on, I
gave my three problem kitties a few drops in a tiny bit of wet food.
There is a lot on the line for my baby cat since she has severe problems
that are affecting her health. More about that and the other cats later.
I have been trying to give her a homeopathic chicken flavored remedy in
her food for a month now and she just won’t eat the food. She smells it
and either eats around it or walks away. I wasn’t sure how this would
go. She took a few tentative licks of her food and then she ate it! All
of it! Woo Hoo! On the other hand, my smart guy mostly Main Coon refused
to eat it, even in two different foods. Hmmmm. He’s going to be a
problem. My third cat, the grouchy one, also ate her food without
complaint. Now that I know who will and won’t take the CBD oil, I have
to give it a few days to see if they continue to cooperate or not and
see there are any significant results. Next time I’ll tell you what I am
dealing with for each cat in detail. In the mean time, wish me luck. Back to Pain Free Hemp Oil Source: https://painfreehempoil.blogspot.com/2019/09/thinking-about-giving-your-cat-cbd-oil.html
The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology
Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects,…
Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects, including memory, pain, reproduction, bone remodeling or immunity, to name a few. Unsurprisingly, given these broad physiological effects, alterations of the ECS have been found in different diseases, including cancer. In recent years, the medical use of cannabis has been approved in different countries for a variety of human conditions. However, the use of these compounds, specifically as anticancer agents, remains controversial. Studies have shown that cannabinoids do have anticancer activity in different tumor types such as breast cancer, melanoma, lymphoma and adult brain cancer. Specifically, phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) has been shown to induce apoptosis and inhibit proliferation of adult cancer cells, as well as modulate angiogenesis and metastasis. Despite increasing evidence that cannabinoids elicit antitumor effects in adult cancers, there is minimal data available on their effects in children or in pediatric cancers despite public and clinical demand for information. Here we describe a comprehensive and critical review of what is known about the effects of cannabinoids on pediatric cancers, highlight current gaps in knowledge and identify the critical issues that need addressing before considering these promising but controversial drugs for use in pediatric oncology.
Keywords: CBD; THC; cannabidiol; cannabinoid; childhood cancer; medical cannabis; pediatric oncology; Δ9-tetrahydrocannabinol.
Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment
Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been…
Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB1), type two (CB2), and the G protein-coupled receptor 55 (GPR55)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in Cannabis sp. raw material is also expressed in their increased bioavailability and penetration through the blood-brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in Cannabis extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases.
Keywords: Cannabis; multitarget; phytocannabinoids (THC and CBD); receptors; terpenes.
Pervasive cropland in protected areas highlight trade-offs between conservation and food security
Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use…
Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use our global synthesis cropland dataset to quantify cropland in protected areas globally and assess their relationship to conservation aims and socio-environmental context. We estimate that cropland occupies 1.4 million km2 or 6% of global protected area. Cropland occurs across all protected area management types, with 22% occurring in strictly protected areas. Cropland inside protected areas is more prevalent in countries with higher population density, lower income inequality, and with higher agricultural suitability of protected lands. While this phenomenon is dominant in midnorthern latitudes, areas of cropland in protected areas of the tropics and subtropics may present greater trade-offs due to higher levels of both biodiversity and food insecurity. Although area-based targets are prominent in biodiversity goal-setting, our results show that they can mask persistent anthropogenic land uses detrimental to native ecosystem conservation. To ensure the long-term efficacy of protected areas, post-2020 goal setting must link aims for biodiversity and human health and improve monitoring of conservation outcomes in cropland-impacted protected areas.
Keywords: CBD; area-based targets; conservation; food security; protected areas.
Conflict of interest statement
The authors declare no competing interest.
- Klein Goldewijk K., Beusen A., Doelman J., Stehfest E.. New anthropogenic land use estimates for the holocene: HYDE 3.2. Earth Syst. Sci. Data. 2017;9:927–953.
- Barrett C. B.. Measuring food insecurity. Science. 2010;327:825–828.
- Fogel R. W.. The Escape from Hunger and Premature Death, 1700-2100: Europe, America, and the Third World. 2004.
- Crist E., Mora C., Engelman R.. The interaction of human population, food production, and biodiversity protection. Science. 2017;356:260–264.
- Pimm S. L., Vijay V.. Population, Agriculture, and Biodiversity: Problems and Prospects. 2020;365.
What are Some Major Factors to Keep in Mind When Buying CBD Vape Oil?
New York Small Business Cooperative License
New York Cannabis Distributor License
Investors in This Cannabis Stock Are Leaving $800 Million on the Table
The USDA Has Released Its Final Rule on Hemp Regulation
New York Cannabis Delivery License
What is Delta-8 THC? Everything You Need to Know
What’s New With Cannabis Stocks for the Week Ending 01/15/21
Cannabis Nursery in New York
New York’s Marijuana Cultivation License
Optical Coherence Tomography Findings in Cannabis Users
Virginia Subcommittee on Marijuana Forms to Debate Legalization Bill
CBD News: Clint Eastwood files third suit against CBD companies, saying they’re falsely claiming endorsement
USDA Issues Final Rule On Hemp
France’s “recreational” cannabis survey • New Mexico governor prioritizes legalization • California eases banking access • & more…
CBD News Roundup: FDA Provides Framework for Future CBD Research
New York’s Adult-Use Processor License
MagicMed: Bringing the Drug Candidate Library Model to Psychedelics
New York Cannabis License Application
Airfield Supply Co. And Kiva Confections Launch Breast Cancer Awareness Campaign
Some Oddly Specific Predictions About Films You Should Keep an Eye Out For This Year
Numinus Announces Grant of Stock Options
EGF Theramed Raises $352,502 in First Tranche of Private Placement
Antioxidant Function of Phytocannabinoids: Molecular Basis of Their Stability and Cytoprotective Properties under UV-irradiation
New York Cannabis Microbusiness License
CBD News: NIHC chairman appointed to board advising U.S. on trade policy
New York Cannabis Dispensary License
Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis
Alcanna to Spin Out Cannabis Business and Pursue Value Segment Strategy
Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units
News1 week ago
Pure Harvest Bolsters Corporate Team with Key Additions
Heartland6 days ago
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
Heartland1 week ago
Compared to Prescription Medication, Medical Cannabis Not Always Affordable Alternative
Heartland1 week ago
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Heartland1 week ago
Novamind Appoints Chuck Rifici to its Board of Directors
Uncategorized1 week ago
Sundial Announces the Launch of Premium Concentrates Products Under its Top Leaf Brand
Heartland1 week ago
Can You Treat COVID-19 With CBD and Reduce Mortality Rates? A New Israeli Research Believes You Can!
Heartland1 week ago
Commentary: LRP1 Is a Master Regulator of Tau Uptake and Spread